Mumbai, India; June XX 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced the launch of Easylax L, the latest addition to its range of offerings under the Easylax franchise, for relief from constipation.
Cipla has previously launched Easylax (Milk of Magnesia & Liquid Paraffin) and Easylax Plus (Milk of Magnesia, Liquid Paraffin & Sodium Picosulfate). Cipla’s new Easylax L variant has 10 gm per 15ml of lactulose as its core ingredient, which helps water inflow into the colon for easy passing of stools.
Easylax L is sugar free and currently available in lemon flavour. The emulsion is available in quantities of 200 ml and 100 ml which is priced at INR 225 and INR 115 respectively. It is available across chemists and on e-pharmacy platforms in India.
Commenting on the new variant, Achin Gupta, CEO, One India Business, Cipla said, “There is immense scope to explore solutions in the constipation segment in India since consumers continue to actively seek remedies to address this through various means like Ayurveda, exercise, medications and home remedies. With the launch of the new variant of Easylax L, we aim to provide a high-quality affordable solution that is also tasty and healthy to our customers to ease their struggle against constipation.”
About Easylax Range
Easylax is available across 4 SKUs for consumers at different stages of constipation.
Easylax & Easylax Plus contains Milk of Magnesia (MOM). It helps in relieving constipation conditions like straining, hard stools, incomplete evacuations. Easylax comes in quantity of 170 ml in pineapple flavour and Easylax Plus is available in 170 ml quantity with a peppermint flavour.
Easylax L contains Lactulose & provides long relief from prolonged constipation. It is available in lemon flavour and in quantities of 100ml and 200ml.
About Cipla:
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar’22), 3rd largest in the pharma private market in South Africa (IQVIA MAT Mar’22), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.
